Core Insights - Septerna, Inc. has appointed Gil Labrucherie as Chief Financial Officer, bringing over 25 years of experience in finance and legal roles within the biopharmaceutical and technology sectors [1][2] - The company is focused on advancing its pipeline of oral small molecule GPCR programs, particularly SEP-786, and expanding its Native Complex Platform for drug discovery [2][4] Company Overview - Septerna, Inc. is a clinical-stage biotechnology company specializing in G protein-coupled receptor (GPCR) drug discovery, utilizing its proprietary Native Complex Platform [4] - The company aims to develop therapies targeting endocrinology, immunology and inflammation, and metabolic diseases [4] Leadership Background - Gil Labrucherie previously served as CFO and CBO at ACELYRIN, overseeing finance, investor relations, and business development [2] - He has raised over 1 billion in value from strategic partnerships throughout his career [2]
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer